Cite
HARVARD Citation
Cheson, B. et al. (2020). Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet. 7 (11), pp. e808-e815. [Online].